The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma
Open accessAbstract
Background Patients with cirrhosis are at high risk of hepatocellular carcinoma (HCC). The SEPT9 gene is a key regulator of cell division and tumor suppressor whose hypermethylation is associated with liver carcinogenesis. The primary aim of this study was to evaluate the diagnostic accuracy of a PCR-based assay for the analysis of SEPT9 promoter methylation in circulating cell-free DNA (m SEPT9 ) for diagnosing HCC among cirrhotic patients. Methods We report two phase II biomarker studies that included cirrhotic patients with or without HCC from France (initial study) and Germany (replication study). All patients received clinical and biological evaluations, and liver imaging according to current recommendations. The primary outcome was defined as the presence of HCC according to guidelines from the American Association for the Study of Liver Diseases. The diagnosis of HCC was confirmed by abdominal contrast-enhanced computed tomography scan and systematically discussed in a multidisciplinary consultation meeting. HCC-free cirrhotic patients were recruited if the screening abdominal ultrasound showed no evidence of HCC at the time of blood sampling for the m SEPT9 test and on the next visit six months later. The adjudicating physicians were blinded to patient results associated with the m SEPT9 test. Findings We included 289 patients with cirrhosis (initial: 186; replication: 103), among whom 98 had HCC (initial: 51; replication: 47). The m SEPT9 test exhibited high diagnostic accuracy for HCC diagnosis, with an area under the receiver operating characteristic curve (AUROC) of 0.944 (0.900–0.970, p<0.0001) in the initial study (replication: 0.930 [0.862–0.971, p<0.0001]; meta-analysis: AUROC=0.940 [0.910–0.970, p<0.0001], no heterogeneity: I 2 =0%, p=0.67; and no publication bias). In multivariate logistic regression analysis, the number of positive m SEPT9 triplicates was the only independent variable significantly associated with HCC diagnosis (initial: OR=6.30, for each m SEPT9 positive triplicate [2.92–13.61, p<0.0001]; replication: OR=6.07 [3.25–11.35, p<0.0001]; meta-analysis: OR=6.15 [2.93–9.38, p<0.0001], no heterogeneity: I 2 =0%, p=0.95; no publication bias). AUROC associated with the discrimination of the logistic regression models in initial and validation studies were 0.969 (0.930–0.989) and 0.942 (0.878–0.978), respectively, with a pooled AUROC of 0.962 ([0.937–0.987, p<0.0001], no heterogeneity: I 2 =0%, p=0.36; and no publication bias). Interpretation Among patients with cirrhosis, the m SEPT9 test constitutes a promising circulating epigenetic biomarker for HCC diagnosis at the individual patient level. Future prospective studies should assess the m SEPT9 test in the screening algorithm for cirrhotic patients to improve risk prediction and personalized therapeutic management of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 2×
“The hypomethylating agents azacitidine and decitabine (5-aza-2′-deoxycytidine) are currently approved for the treatment of several specific forms of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, and are currently being investigated for use in non-hematological cancers (Kantarj…”
BackgroundLeening, M. J. G., Vedder, M. M., Witteman, J. C. M., Pencina, M. J., & Steyerberg, E. W. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1522 · Cited by 594
Cited by
Epigenetics in Human Obesity and Type 2 Diabetes
Ling, C., & Rönn, T. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.03.009 · Cited by 941
DNA Methylation Cancer Biomarkers: Translation to the Clinic
Locke, W. J., Guanzon, D., Ma, C., Liew, Y. J., Duesing, K. R., Fung, K. Y. C., & Ross, J. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01150 · Cited by 472
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Liquid biopsy in the clinical management of hepatocellular carcinoma
von Felden, J., Garcia-Lezana, T., Schulze, K., Losic, B., & Villanueva, A. (2020) · Gut · doi:10.1136/gutjnl-2019-320282 · Cited by 141
Metadata
- Authors
- Oussalah, A., Rischer, S., Bensenane, M., Conroy, G., Filhine-Tresarrieu, P., Debard, R., Forest-Tramoy, D., Josse, T., Reinicke, D., Garcia, M., Luc, A., Baumann, C., Ayav, A., Laurent, V., Hollenbach, M., Ripoll, C., Guéant-Rodriguez, R.-M., Namour, F., Zipprich, A., Fleischhacker, M., Bronowicki, J.-P., & Guéant, J.-L.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 30
- Pages
- 138-147
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2794450296
- Cited by
- 164
- References
- 4
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1016/j.ebiom.2018.03.029
- The paper
- Oussalah, A., Rischer, S., Bensenane, M., Conroy, G., Filhine-Tresarrieu, P., Debard, R., Forest-Tramoy, D., Josse, T., Reinicke, D., Garcia, M., Luc, A., Baumann, C., Ayav, A., Laurent, V., Hollenbach, M., Ripoll, C., Guéant-Rodriguez, R.-M., Namour, F., Zipprich, A., . . . Guéant, J.-L. (2018). Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. eBioMedicine. https://doi.org/10.1016/j.ebiom.2018.03.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.